Verition Fund Management
ZVRA icon

Verition Fund Management’s Zevra Therapeutics ZVRA Stock Holding History

Verition Fund Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,704
Closed -$159K – 3690
2025
Q4 		$159K Sell
17,704
-175,805
-91% -$1.66M ﹤0.01% 3237
2025
Q3 		$1.84M Buy
+193,509
New +$1.94M 0.01% 2044
2025
Q2 		– Sell
-22,520
Closed -$169K – 3913
2025
Q1 		$169K Buy
+22,520
New +$179K ﹤0.01% 3086
2023
Q1 		– Sell
-10,100
Closed -$46.4K – 2623
2022
Q4 		$46.4K Buy
+10,100
New +$51.3K ﹤0.01% 1892

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Verition Fund Management's ZVRA Position: Q1 2026 in Review

Verition Fund Management sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 17,704 shares — an estimated $159K sold.

Verition Fund Management first reported a position in ZVRA in Q4 2022 and held it in 4 quarters. The position peaked at $1.84M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Verition Fund Management reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 17,704 Zevra Therapeutics shares in Q1 2026, an estimated $159K.
  • Verition Fund Management first reported a position in Zevra Therapeutics in Q4 2022 and held it in 4 quarters.
  • Verition Fund Management's Zevra Therapeutics position peaked at $1.84M in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.